Please ensure Javascript is enabled for purposes of website accessibility
CASE REPORT
Acquired haemophilia A: a case report
 
More details
Hide details
1
Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Lodz, Poland
 
 
Submission date: 2016-12-20
 
 
Acceptance date: 2017-04-24
 
 
Publication date: 2017-09-30
 
 
Medical Studies 2017;33(3):227-231
 
KEYWORDS
TOPICS
ABSTRACT
Acquired haemophilia A is rare, autoimmune bleeding disorder caused by the production of autoantibodies against coagulation factor VIII (FVIII). The disorder affects 1.5 people per 1 million population a year, particularly the elderly. Unlike congenital haemophilia, the disease occurs in a similar proportion of men and women. An 86-year-old patient was admitted to the Department of Internal Medicine and Pharmacology with anaemia, progressive weakness, bruising in the subcutaneous tissue, and generaliesd stiffness of joints. Routine blood tests revealed isolated prolongation of activated partial thromboplastin time (aPTT) above 100 s. Activated partial thromboplastin time mixing test also showed prolongation of aPTT equal to 104.2 s. Factor VIII activity was 2%. The patient was referred to the Haematology Department, where a positive titre of anticoagulant 11 (BU) was obtained. After diagnosing acquired haemophilia A, the patient was administered activated prothrombin complex concentrate and prednisone, which resulted in clinical improvement and shortening of aPTT.
REFERENCES (13)
1.
Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, Mingot Castellano ME, Shima M, St-Louis J. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-75.
 
2.
Knoebl P, Marco P, Baudo F, Collins P, Huth-Ku¨hne A, Nemes L, Pellegrini F, Tengborn L, Le´vesque H, on behalf of the EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10: 622-31.
 
3.
Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol 2010; 148: 183-94.
 
4.
Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CRM. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007; 109: 1870-7.
 
5.
Sakurai Y, Takeda T. Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder. J Immunol Res 2014; 2014: 320674.
 
6.
Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano MEM, Shima M, St-Louis J, Lévesque H. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 3: 161.
 
7.
Chojnowski K, Podolak-Dawidziak M, Windyga J. Diagnosis of the prolonged activated partial thromboplastin time (aPTT). Hem 2010; 1: 81-6.
 
8.
Zawilska K, Chojnowski K, Klukowska A, Łętowska M, Mital A, Musiał J, Podolak-Dawidziak M, Undas A, Windyga J, Zdziarska J. Polish guidelines for the management of rare clotting factor deficiencies. Hem 2011; 2: 303-10.
 
9.
Windyga J, Chojnowski K, Klukowska A, Łętowska M, Mital A, Podolakdawidziak M, Zdziarska J, Zawilska K. Polish guidelines for the management of inherited bleeding disorders caused by coagulation factor deficiency. Acta Haematol Pol 2008; 39: 537-64.
 
10.
Iwaniec T. Diagnostics of von Willebrand disease. J Transf Med 2011; 4: 178-82.
 
11.
Wygonowska EM, Zdrodowska-Stefanow B. Zespół antyfosfolipidowy. Wiad Lek 2005; 58: 116-23.
 
12.
Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost 2014; 40: 803-11.
 
13.
Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost 2009; 35: 760-8.
 
eISSN:2300-6722
ISSN:1899-1874
Journals System - logo
Scroll to top